# R3 Vascular

> R3 Vascular develops drug-eluting bioresorbable scaffolds for peripheral arterial disease. Its investigational MAGNITUDE system combines temporary vessel support with sirolimus delivery and is being evaluated in the randomized ELITE-BTK pivotal trial.

- **Founded:** 2019
- **Headquarters:** Mountain View, United States
- **Founders:** Kamal Ramzipoor (Founder and Chief Technology Officer; former CEO)
- **Products:** MAGNITUDE
- **Notable:** Closed Series A in October 2020 and Series B in May 2024., Announced FDA IDE approval for ELITE-BTK in November 2024., Announced the first ELITE-BTK patient treated in April 2025.

## Products & services

- **MAGNITUDE** — Investigational sirolimus-eluting, poly(L-lactide)-based bioresorbable scaffold and delivery system for below-the-knee arterial disease; 98-micron struts are reported by the company.

## Achievements

- Closed Series A in October 2020 and Series B in May 2024.
- Announced FDA IDE approval for ELITE-BTK in November 2024.
- Announced the first ELITE-BTK patient treated in April 2025.
- RESOLV I findings published online in July 2025, with print publication in April 2026.

## Latest updates

- **2026-09** — Lisa Wipperman Heine appointed to the board on September 21, adding clinical strategy, reimbursement and commercialization experience.
- **2026-08** — Robert Spanos appointed VP, Global Market Development; Katie Segreto appointed VP, Finance and Corporate Controller.
- **2026-04** — RESOLV I paper appeared in the April 2026 issue of European Journal of Vascular and Endovascular Surgery; first published online July 10, 2025.
- **2026-02** — ELITE-BTK registry update lists recruiting status, estimated enrollment of 300 and estimated primary completion in March 2028.

## Links

- Website: https://www.r3vascular.com/
- LinkedIn: https://www.linkedin.com/company/r3-vascular-inc/

---

Profile page: https://yespress.io/r3-vascular
Published by YesPress — https://yespress.io
Last updated: 2026-09-30